Provided by Tiger Trade Technology Pte. Ltd.

Incyte

113.44
+0.71000.63%
Post-market: 113.40-0.0400-0.04%16:51 EDT
Volume:1.27M
Turnover:145.13M
Market Cap:22.99B
PE:14.45
High:115.49
Open:112.82
Low:112.46
Close:112.73
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.60
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.62
PE(LYR):17.70

Loading ...

Incyte Corporation : H.c. Wainwright Raises Target Price to $152 from $150

THOMSON REUTERS
·
Sep 28

JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating

MT Newswires Live
·
Sep 28

Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA

MT Newswires Live
·
Sep 28

Incyte : JP Morgan Raises Target Price to $123 from $120

THOMSON REUTERS
·
Sep 28

Incyte (INCY) Gets a Hold from Bernstein

TIPRANKS
·
Sep 26

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (Zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Sep 26

FDA approves Incyte’s Atebrioz for fibrodysplasia ossificans progressiva

TIPRANKS
·
Sep 26

US FDA Approves Mirum's Drug for Rare Bone Disorder

Reuters
·
Sep 26

FDA: Approves Atebrioz (Zilurgisertib) for Fibrodysplasia Ossificans Progressiva in Adults & Pediatric Patients 12 Years + - Website

THOMSON REUTERS
·
Sep 26

FDA : Atebrioz Recommended Dosage 100 Mg Once Daily

THOMSON REUTERS
·
Sep 26

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 23

Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says

MT Newswires Live
·
Sep 22

Incyte Price Target Maintained with a $109.00/Share by RBC Capital

Dow Jones
·
Sep 22

Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026

Reuters
·
Sep 22

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Incyte Expands Skin Diseases Treatment Partnership in Australia

MT Newswires Live
·
Sep 21

Specialised Therapeutics expands partnership with Incyte to include Opzelura

TIPRANKS
·
Sep 21

AFLAC, CME, Incyte, Box, Five Below Insider Shake-Up

TIPRANKS
·
Sep 19

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 18

Incyte R&D President Pablo J. Cagnoni Disposes of 23,218 Common Shares Worth $2.8 Million

Reuters
·
Sep 18